Katsuyoshi Hori
Department of Vascular Biology
Division of Cancer Control
Institute of Development
Aging and Cancer
Japan
Name/email consistency: high
- Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism. Hori, K. Cancer Metastasis Rev. (2011)
- The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors. Hori, K., Nishihara, M., Shiraishi, K., Yokoyama, M. J. Pharm. Sci (2010)
- Vital microscopic analysis of polymeric micelle extravasation from tumor vessels: macromolecular delivery according to tumor vascular growth stage. Hori, K., Nishihara, M., Yokoyama, M. J. Pharm. Sci (2010)
- Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Hori, K., Furumoto, S., Kubota, K. Cancer Sci. (2008)
- Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Hori, K. Chemotherapy (2005)
- Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Hori, K., Saito, S. Br. J. Cancer (2004)
- Effect of irradiation on neovascularization in rat skinfold chambers: implications for clinical trials of low-dose radiotherapy for wet-type age-related macular degeneration. Hori, K., Saito, S., Tamai, M. Int. J. Radiat. Oncol. Biol. Phys. (2004)
- Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Hori, K., Saito, S., Sato, Y., Akita, H., Kawaguchi, T., Sugiyama, K., Sato, H. Eur. J. Cancer (2003)
- Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Hori, K., Saito, S. Br. J. Cancer (2003)
- A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Hori, K., Saito, S., Kubota, K. Br. J. Cancer (2002)
- Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Hori, K., Saito, S., Sato, Y., Kubota, K. Med. Sci. Monit. (2001)
- Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Hori, K., Saito, S., Takahashi, H., Sato, H., Maeda, H., Sato, Y. Jpn. J. Cancer Res. (2000)
- Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Hori, K., Saito, S., Nihei, Y., Suzuki, M., Sato, Y. Jpn. J. Cancer Res. (1999)